Figure 1. DOT1L is highly expressed in B cell lymphoma cells.(A) The relative expression of DOT1L between hematological malignancies and normal tissues was analyzed by the TCGA database. (B) The basal protein level of DOT1L effector H3K79me2 was examined in several B cell lymphoma cells by Wesrern blot. H3 served as loading controls.
3.2 Silencing DOT1L significantly inhibits the growth of B lymphoma cells
To examine the character of DOT1L in B lymphoma cell, Raji, MV4-11, and Jurkat (acute lymphoblastic leukemia) cells were transfected with siRNA targeting DOT1L, respectively. The silencing efficiency of DOT1L was indicated by the reduction of H3K79 (Figure 2A). It has been reported that DOT1L is an important oncogene in the MLL-rearranged cell line MV4-11 [18], therefore MV4-11 was taken as the positive control. Knockdown of DOT1L remarkably attenuated the viability of Raji (Figure 2B), whereas the viability of Jurkat cells was not affected, correlating with the findings of a previous research [18]. These data revealed that DOT1L also played an oncogenic role in B lymphoma.